29 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Oct 2038. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Oct 2038
Next term end
7
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Oct 2038 · Low confidence
Also notable
Ends no later than Apr 2040 · Medium confidence
Also notable
Ends Mar 2039 · Medium confidence
Preparation of Psilocybin, Different Polymorphic Forms, Intermediates, Formulations and Their Use
US 11,629,159
Cited by 18 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2038. A terminal disclaimer caps this term to an earlier patent's.
Method for Treating Anxiety Disorders, Headache Disorders, and Eating Disorders with Psilocybin
US 11,564,935
Cited by 26 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2040. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Processes for the Production of Tryptamines
US 11,136,293
Cited by 13 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2039.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 30, 2026The maintenance fee for Processes for the Production of Tryptamines (US 11,661,617) comes due Nov 30, 2026. Unpaid by Jun 1, 2027, it lapses early.
- 1 fee due Feb 28, 2027The maintenance fee for Method for Treating Anxiety Disorders, Headache Disorders, and Eating Disorders with Psilocybin (US 11,738,035) comes due Feb 28, 2027. Unpaid by Aug 30, 2027, it lapses early.
- 2 fees due Jun 26 to 30, 2027 · next Jun 26
- 1 fee due Jul 9, 2027The maintenance fee for Method for Treating Anxiety Disorders, Headache Disorders, and Eating Disorders with Psilocybin (US 11,865,126) comes due Jul 9, 2027. Unpaid by Jan 10, 2028, it lapses early.
- 1 fee due Sep 26, 2027The maintenance fee for Preparation of Psilocybin, Different Polymorphic Forms, Intermediates, Formulations and Their Use (US 11,939,346) comes due Sep 26, 2027. Unpaid by Mar 27, 2028, it lapses early.
Recent changes
- 4 of the patents on this record were granted since Aug 16, 2026
What they patent
The 5 largest of its 7 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Preparation of Psilocybin, Different Polymorphic Forms, Intermediates, Formulations and Their Use | 15 in force | to Dec 2038 |
| Methods for Treating Anxiety Disorders, Headache Disorders, and Eating Disorders with Psilocybin | 7 in force | to Jul 2041 |
| Processes for the Production of Tryptamines | 3 in force | to Mar 2039 |
| Novel Safrylamine Derivatives Having Prodrug Properties | 1 in force | to Nov 2043 |
| Computing N-Dimensional Sentiment Using a Large Language Model | 1 in force | to Nov 2043 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,519,175 | Preparation of Psilocybin, Different Polymorphic Forms, Intermediates, Formulations and Their Use In force · High confidence | In force | High confidence | |
| US 10,947,257 | Preparation of Psilocybin, Different Polymorphic Forms, Intermediates, Formulations and Their Use In force · High confidence | In force | High confidence | |
| US 10,954,259 | Preparation of Psilocybin, Different Polymorphic Forms, Intermediates, Formulations and Their Use In force · High confidence | In force | High confidence | |
| US 11,180,517 | Preparation of Psilocybin, Different Polymorphic Forms, Intermediates, Formulations and Their Use In force · Low confidence | In force | Low confidence | |
| US 11,447,510 | Preparation of Psilocybin, Different Polymorphic Forms, Intermediates, Formulations and Their Use In force · Low confidence | In force | Low confidence | |
| US 11,505,564 | Preparation of Psilocybin, Different Polymorphic Forms, Intermediates, Formulations and Their Use In force · High confidence | In force | High confidence | |
| US 11,629,159 | Preparation of Psilocybin, Different Polymorphic Forms, Intermediates, Formulations and Their Use In force · Low confidence | In force | Low confidence | |
| US 11,851,451 | Preparation of Psilocybin, Different Polymorphic Forms, Intermediates, Formulations and Their Use In force · High confidence | In force | High confidence | |
| US 11,939,346 | Preparation of Psilocybin, Different Polymorphic Forms, Intermediates, Formulations and Their Use In force · High confidence | In force | High confidence | |
| US 12,312,375 | Preparation of Psilocybin, Different Polymorphic Forms, Intermediates, Formulations and Their Use In force · Low confidence | In force | Low confidence |
Also on record, not counted in the 29: 27 applications pending · 1 application abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.